Bladder cancer is a serious health concern. The first line of treatment is transurethral resection, and a precise evaluation of the tumor margins may call for full tumor removal. Cancer cells frequently display proliferative potential and genomic instability. Intraoperative Flow Cytometry (iFC), a next-generation margin evaluation tool for assessing DNA content, has previously been shown to be useful in the detection of several malignancies. In the current study, we looked into the potential utility of iFC for identifying bladder cancer following surgery. The entire iFC evaluation process takes 3 minutes to 5 minutes per sample and includes a two-step analysis that includes calculating the DNA-index and tumor-index. 24 hyperploid and one hypoploid tumors were first discovered through DNA-index computation. Furthermore, tumor samples can be identified from normal cells by virtue of their significantly increased proliferation potential, according to results of cell cycle analysis and Tumor-index computation. The pathology assessment was used as the benchmark for iFC evaluation, and it was found that our methodology has a 98% accuracy rate in identifying the presence of cancer cells in a particular sample. Our findings suggest future examination of the utility of iFC as a cutting-edge technique for evaluating malignancy during transurethral resections.
